Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Loomba

Showing results (221-230 of 750) with videos related to

Pageof 75
Sort By:
Journal of Clinical Medicine|April 27, 2024
Potential Therapeutic Targets in Obesity, Sleep Apnea, Diabetes, and Fatty Liver DiseaseChristina Gu, Nicole Bernstein, Nikita Mittal, et al.
The American Journal of Gastroenterology|June 23, 2026
PREVALENCE AND RISK FACTORS ASSOCIATED WITH MASLD AND ADVANCED FIBROSIS AMONG OVERWEIGHT INDIVIDUALS: IMPLICATIONS FOR SCREENING GUIDELINESMaria Mironova, Kaleb Tesfai, Egbert Madamba, et al.
Lancet (London, England)|August 23, 2025
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trialRohit Loomba, Erin Morgan, Keyvan Yousefi, et al.
Alimentary Pharmacology & Therapeutics|May 9, 2020
Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitisBjörn Carlsson, Daniel Lindén, Gabriella Brolén, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2010
Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in menRohit Loomba, Hwai-I Yang, Jun Su, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 29, 2024
Global Prevalence of Advanced Liver Fibrosis and Cirrhosis in the General Population: A Systematic Review and Meta-analysisMohammad Zamani, Shaghayegh Alizadeh-Tabari, Veeral Ajmera, et al.
Nature Reviews. Gastroenterology & Hepatology|May 12, 2018
The gut-liver axis and the intersection with the microbiomeAnupriya Tripathi, Justine Debelius, David A Brenner, et al.
Alimentary Pharmacology & Therapeutics|November 15, 2025
Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD, MetALD and ALDNobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, et al.
Hepatology (Baltimore, Md.)|September 3, 2013
Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in miceLing Yang, Yoon Seok Roh, Jingyi Song, et al.
The Lancet. Oncology|June 2, 2022
Clinical features and outcomes of NAFLD-related hepatocellular carcinoma - Authors' replyDarren Jun Hao Tan, Cheng Han Ng, Mark D Muthiah, et al.
Pageof 75

Showing results (221-230 of 750) with videos related to

Sort By:
Pageof 75
Journal of Clinical Medicine|April 27, 2024
Potential Therapeutic Targets in Obesity, Sleep Apnea, Diabetes, and Fatty Liver DiseaseChristina Gu, Nicole Bernstein, Nikita Mittal, et al.
The American Journal of Gastroenterology|June 23, 2026
PREVALENCE AND RISK FACTORS ASSOCIATED WITH MASLD AND ADVANCED FIBROSIS AMONG OVERWEIGHT INDIVIDUALS: IMPLICATIONS FOR SCREENING GUIDELINESMaria Mironova, Kaleb Tesfai, Egbert Madamba, et al.
Lancet (London, England)|August 23, 2025
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trialRohit Loomba, Erin Morgan, Keyvan Yousefi, et al.
Alimentary Pharmacology & Therapeutics|May 9, 2020
Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitisBjörn Carlsson, Daniel Lindén, Gabriella Brolén, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2010
Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in menRohit Loomba, Hwai-I Yang, Jun Su, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 29, 2024
Global Prevalence of Advanced Liver Fibrosis and Cirrhosis in the General Population: A Systematic Review and Meta-analysisMohammad Zamani, Shaghayegh Alizadeh-Tabari, Veeral Ajmera, et al.
Nature Reviews. Gastroenterology & Hepatology|May 12, 2018
The gut-liver axis and the intersection with the microbiomeAnupriya Tripathi, Justine Debelius, David A Brenner, et al.
Alimentary Pharmacology & Therapeutics|November 15, 2025
Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD, MetALD and ALDNobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, et al.
Hepatology (Baltimore, Md.)|September 3, 2013
Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in miceLing Yang, Yoon Seok Roh, Jingyi Song, et al.
The Lancet. Oncology|June 2, 2022
Clinical features and outcomes of NAFLD-related hepatocellular carcinoma - Authors' replyDarren Jun Hao Tan, Cheng Han Ng, Mark D Muthiah, et al.
Pageof 75